Sun Pharma’s US sales grew sequentially, aiding both sales and Ebitda growth, Q4 results showed. While these will also see costs increase due to hiring and marketing, they should contribute to revenue growth too in the medium to long term. The market itself is recovering and Sun Pharma’s domestic growth in FY19 should look better, barring any uncertainty caused by government policy. Overall, Sun Pharma’s revenue in the March quarter declined by 2.2% over a year ago and rose by 4.9% sequentially. If none of that happens, then FY19 may well be the year when Sun Pharma finally sees some sunshine on the valuation front.

Source: Mint May 28, 2018 03:45 UTC